序号 |
标题 |
次数 |
作者 |
发布时间 |
74971 |
5,10,15,20-四(4-甲氧羰基苯基)卟啉(TCMPP) |
127 |
WYQ |
2024-12-24 |
74972 |
N3-PEG4-C2-Pfp ester CAS:1353012-00-6 |
94 |
h |
2024-12-24 |
74973 |
mPEG40-OH cas:1346556-95-3 甲氧基四十聚乙二醇-羟基 |
108 |
zyl |
2024-12-24 |
74974 |
PC:Chol:PEG2000-ATP Liposome (PEGylated),PC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
141 |
axc |
2024-12-24 |
74975 |
perfluorophenyl 4-(pyridin-2-yldisulfanyl)butanoate ,PDB-PFP,2088570-81-2,ADC试剂 |
103 |
hyy |
2024-12-24 |
74976 |
Ald-Ph-amido-PEG3-C1-Boc CAS:1007215-94-2 |
81 |
h |
2024-12-24 |
74977 |
2 5 8 11-Tetraoxaheptadecane-17-thiol cas:205490-80-8 |
133 |
zyl |
2024-12-24 |
74978 |
72573-82-1,Gd-DOTA,钆特酸,大环化合物 |
115 |
kx |
2024-12-24 |
74979 |
PS:PC:Chol:PEG2000-ATP Liposome (PEGylated),PS:PC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
173 |
axc |
2024-12-24 |
74980 |
mPEG45-SSG的结构式 |
108 |
zyl |
2024-12-24 |
74981 |
DOTA satoreotide,大环化合物 |
95 |
kx |
2024-12-24 |
74982 |
PS:PC:Chol:PEG2000-ATP Liposome (PEGylated),PS:PC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
189 |
axc |
2024-12-24 |
74983 |
mPEG62-OH 甲氧基六二聚乙二醇-羟基 |
140 |
zyl |
2024-12-24 |
74984 |
DOTA-甲基四嗪,1610950-41-8,DOTA-多肽分子探针 |
92 |
kx |
2024-12-24 |
74985 |
mPEG45-OH 甲氧基四十五聚乙二醇-羟基 |
123 |
zyl |
2024-12-24 |
74986 |
DOPG:DOPC:Chol:PEG2000-ATP Liposome (PEGylated),DOPG:DOPC:胆固醇:聚乙二醇2000-ATP脂质体(聚乙二醇化) |
222 |
axc |
2024-12-24 |
74987 |
2,5-Dioxo-1-(4-(pyridin-2-yldisulfanyl)butanoyloxy)pyrrolidine-3-sulfonic acid,SPDB-sulfo,1628113-16-5,抗体- 药物偶联物 |
83 |
hyy |
2024-12-24 |
74988 |
5-(4-羧基苯基)-10,15,20-四苯基镁卟啉(MgTPPCOOH) |
104 |
WYQ |
2024-12-24 |
74989 |
mPEG1-OCH2CH2COONHS Ester cas:1127247-34-0 |
110 |
zyl |
2024-12-24 |
74990 |
1610950-41-8,DOTA-MeTz,DOTA-甲基四嗪,大环化合物 |
122 |
kx |
2024-12-24 |
74991 |
橙红色固体5,15-二(4-乙炔基苯基)-10,20-二苯基钴卟啉(CoDETPP) |
129 |
WYQ |
2024-12-24 |
74992 |
原卟啉二甲酯钴配合物PPDMECo |
101 |
WYQ |
2024-12-24 |
74993 |
DOPG:胆固醇:聚乙二醇2000-ATP脂质体(聚乙二醇化),DOPG:Chol:PEG2000-ATP Liposome (PEGylated) |
166 |
axc |
2024-12-24 |
74994 |
mPEG15-OCH2CH2COOH的介绍 |
103 |
zyl |
2024-12-24 |
74995 |
127985-74-4,(p-SCN-Bn)-dota,2-[(4-异硫氰基苯基)甲基]-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸,大环化合物 |
98 |
kx |
2024-12-24 |
74996 |
N-Succinimidyl 4-(2-pyridyldithio)butanoate,SPDB,115088-06-7,ADC试剂 |
114 |
hyy |
2024-12-24 |
74997 |
对照阿仑膦酸盐脂质体(阴离子),Control Alendronate Liposome (Anionic) |
146 |
axc |
2024-12-24 |
74998 |
mPEG44-OCH2COOH的介绍 |
114 |
zyl |
2024-12-24 |
74999 |
5-对-(对羰基苯甲酸)-氨基苯基-10,15,20-三苯基卟啉锌(Ⅱ)Zn(p-CPTPP) |
127 |
WYQ |
2024-12-24 |
75000 |
1189194-65-7,DOTA-CH2-Alkynyl (TFA salt),大环化合物 |
95 |
kx |
2024-12-24 |
75001 |
Alendronate Liposome (Anionic) 阿仑膦酸盐脂质体(阴离子) |
166 |
axc |
2024-12-24 |
75002 |
meso-四(4-甲基-3-磺酸苯基)卟啉[简称T(4-MP)PS4] |
145 |
WYQ |
2024-12-24 |
75003 |
mPEG9-OCH2COOH的结构式 |
115 |
zyl |
2024-12-24 |
75004 |
SPDMB,2,5-dioxopyrrolidin-1-yl 3-methyl-3-(pyridin-2-yldisulfanyl)butanoate,2101206-29-3,抗体- 药物偶联物 |
133 |
hyy |
2024-12-24 |
75005 |
PAMAM-DOTA-Gd,大环化合物 |
85 |
kx |
2024-12-24 |
75006 |
四(4-溴苯基)卟啉银(AgTBrPP),AgTBrPP是一种含银的金属卟啉配合物。 |
149 |
WYQ |
2024-12-24 |
75007 |
mPEG36-NH-Mal 甲氧基三十六聚乙二醇-NH-马来酰亚胺 |
158 |
zyl |
2024-12-24 |
75008 |
DOTA-TATE,177943-88-3,大环化合物 |
119 |
kx |
2024-12-24 |
75009 |
meso-四(3-氯苯基)卟啉(T(3-C1P)P) |
103 |
WYQ |
2024-12-24 |
75010 |
mPEG48-OCH2CH2COOH cas:125220-94-2 |
143 |
zyl |
2024-12-24 |
75011 |
对照阿仑膦酸盐脂质体(中性),Control Alendronate Liposome (Neutral) |
101 |
axc |
2024-12-24 |
75012 |
甲基丙烯酸十二烷氧基四苯基卟啉(MM-TPP-12C) |
104 |
WYQ |
2024-12-24 |
75013 |
mPEG36-OH cas:2633587-48-9 cas:114740-40-8 甲氧基三十六聚乙二醇-羟基 |
156 |
zyl |
2024-12-24 |
75014 |
DOTA-(酪氨酸3)-奥曲肽,204318-14-9,DOTA-TOC,大环化合物 |
81 |
kx |
2024-12-24 |
75015 |
Alendronate Liposome (Neutral),阿仑膦酸盐脂质体(中性) |
125 |
axc |
2024-12-24 |